Elansary, M., Alkafaji, H., Al-Hilli, N. (2023). Diagnostic Evaluation of Immunohistochemical Expression of p16 and ki67 in Ovarian Serous Neoplasms. Alustath, 22(2), 183-191. doi: 10.52573/ipmj.2023.180588
Muna Fawzi Elansary; Haider Abdul Ridha Alkafaji; Nadia Mudher Al-Hilli. "Diagnostic Evaluation of Immunohistochemical Expression of p16 and ki67 in Ovarian Serous Neoplasms". Alustath, 22, 2, 2023, 183-191. doi: 10.52573/ipmj.2023.180588
Elansary, M., Alkafaji, H., Al-Hilli, N. (2023). 'Diagnostic Evaluation of Immunohistochemical Expression of p16 and ki67 in Ovarian Serous Neoplasms', Alustath, 22(2), pp. 183-191. doi: 10.52573/ipmj.2023.180588
Elansary, M., Alkafaji, H., Al-Hilli, N. Diagnostic Evaluation of Immunohistochemical Expression of p16 and ki67 in Ovarian Serous Neoplasms. Alustath, 2023; 22(2): 183-191. doi: 10.52573/ipmj.2023.180588

Diagnostic Evaluation of Immunohistochemical Expression of p16 and ki67 in Ovarian Serous Neoplasms

Iraqi Postgraduate Medical Journal
Volume 22, Issue 2, April 2023, Pages 183-191    PDF (437.5 K)
Document Type: Research Paper
DOI: 10.52573/ipmj.2023.180588
Authors
Muna Fawzi Elansary1; Haider Abdul Ridha Alkafaji2; Nadia Mudher Al-Hilli3
1Dept. of Histopathology, Iraqi Board for Medical Specialties, Babil Center, Iraq.
2Dept. of Pathology, Babil College of Medicine, University of Babylon -Iraq .
3Dept. of gynecology, Babil College of Medicine, University of Babylon –Iraq.
Abstract
BACKGROUND:
Ovarian serous neoplasms are the most common type of epithelial ovarian tumors, classified as Low-Grade Serous Neoplasia (inclusive of benign serous cyst adenoma, borderline serous tumors, low grade serous carcinoma) and High-Grade Serous Carcinoma. P16 is a cyclin-dependent kinase-IV inhibitor that mediates its action through inhibitory effect on the cell cycle, Ki-67 determine the proliferating cells of the tumor, is strictly connected with cellular cycle.
OBJECTIVE:
The aim of the present study is to diagnostic evaluate of p16 and ki67 protein expression in of ovarian serous tumors in Iraqi patients.
MATERIAL AND METHODS:
52 cases of ovarian serous tumors specimens were studied. Using p16 (Mouse monoclonal p16 antibody, Cytoplasm and Nuclear expression) and ki67 (monoclonal mouse antihuman Ki-67/MIB-1 antibody, Nuclear expression).
RESULTS:                      
There is a significant correlation of p16 and ki67 expression in ovarian serous tumors. P16 Immune reactive score cases with score 3 of high grade serous carcinoma 69.2%, low grade serous carcinoma  7.7%, borderline serous 15.4%, and no any case of ovarian serous cyst adenoma. Ki67 labeling index expression in all cases of  ovarian serous cyst adenoma, 76.92% borderline tumors, 92.96% low grade serous tumors with low labeling index. While 100% high grade serous carcinoma, 23.07% borderline tumors, 7.7% low grade serous carcinoma with high ki67 labeling index.
CONCLUSION:
Significant correlation of  p16 expression  in ovarian serous tumors, with strong diffuse expression in high grade serous carcinoma. P16 can be used as a diagnostic marker. Ki67 has been reported to be of             a diagnostic value  in differentiation of  low grade serous carcinoma from high grade serous carcinoma.
 
 
Keywords
Ovarian serous neoplasms; P16 and Ki67
References
REFERENCE:

  1. Goldblum J, Lamps L, McKenney J, Myers J. Rosai and Ackerman's surgical pathology. 11th ed. Philadelphia, PA: Elsevier; 2018;1375-79.
  2. Nucci M, Parra-Herran C. Gynecologic pathology. 2nd ed. philadelphia, PA19103- 2899: Elsevier; 2019; 579-602.
  3. Hauptmann S, Friedrich K, Redline R, Avril S. Ovarian borderline tumors in the 2014 WHO classification: evolving concepts and diagnostic criteria. Virchows Archiv. 2016;470:125-42.
  4. Ahn G, Folkins A, McKenney J, Longacre T. Low-grade Serous Carcinoma of the Ovary. American Journal of Surgical Pathology. 2016;40:1165-76.
  5. Hussein MJ, Salai JS. Clinical and histopathological features of ovarian cancer in Rizgary Hospital/Erbil City from 2014 to 2017. Med J Babylon 2019;16:112-18
  6. Wing-Cheuk Wong R, Palicelli A, Hoang L, Singh N. Interpretation of p16, p53 and mismatch repair protein immunohistochemistry in gynaecological neoplasia. Diagnostic Histopathology. 2020;26:257-77.
  7. Rabban J, Soslow R, Zaloudek C. Immunohistology of the Female Genital Tract. Diagnostic Immunohistochemistry. 2010;:690-762.
  8. Li J, Poi MJ, Tsai MD. Regulatory mechanisms of tumor suppressor P16(INK4A) and their relevance to cancer. Biochemistry 2011;50:5566e82.
 

  1. Sundov D, Caric A, Mrklic I, Gugic D, Capkun V, Hofman I et al. P53, MAPK, topoisomerase II alpha and Ki67 immunohistochemical expression and KRAS/BRAF mutation in ovarian serous carcinomas. Diagnostic Pathology. 2013;8.
  2. Laishram S, Gupta V, Bhake A, Wankhede A, Agrawal D. To assess the utility of proliferative marker Ki-67 in surface epithelial ovarian tumor. Journal of Datta Meghe Institute of Medical Sciences University. 2019;14:6.
  3. Agrawal P, Kulkarni D, Chakrabarti P, Chourasia S, Dixit M, Gupta K. Clinicopathological spectrum of ovarian tumors: A 5-year experience in a tertiary health care center. Journal of Basic and Clinical Reproductive Sciences. 2015;4:90.
  4. Begum S, Begum F, Gani N, Rahman F, Jahan F. Relationship of Age and Different Histological Types of Ovarian Tumors. Bangladesh Journal of Obstetrics & Gynaecology. 2017;32:99-105.
  5. Deng F, Xu X, Lv M, Ren B, Wang Y, Guo W et al. Age is associated with prognosis in serous ovarian carcinoma. Journal of Ovarian Research. 2017;10.
  6. Ali M, Seadah S, Attiah S. Significance of E-cadherin and KI67 expression in ovarian serous tumors. Egyptian Journal of Pathology. 2019;39:349.
  7. O'Neill C, McBride H, Connolly L, Deavers M, Malpica A, McCluggage W. High-grade ovarian serous carcinoma exhibits significantly higher p16 expression than low-grade serous carcinoma and serous borderline tumour. Histopathology. 2007;50:773-79.
  8. O. Nazlioglu,İ. Ercan2, T. Bilgin,S. Ozuysal Expression of p16 in serous ovarian neoplasms. 2010;31:312-14.
  9. Schlosshauer P, Deligdisch L, Penault-Llorca F, Fatemi D, Qiao R, Yao S et al. Loss of p16INK4A Expression in Low-grade Ovarian Serous Carcinomas. International Journal of Gynecological Pathology. 2011;30:22-29.
  10. Sallum L, Andrade L, Ramalho S, Ferracini A, de Andrade Natal R, Brito A et al. WT1, p53 and p16 expression in the diagnosis of low- and high-grade serous ovarian carcinomas and their relation to prognosis. Oncotarget. 2018;9:15818-27.
 

  1. Manu V, Hein T, Boruah D, Srinivas V. Serous ovarian tumors: Immunohistochemical profiling as an aid to grading and understanding tumorigenesis. Medical Journal Armed Forces India. 2018;76:30-36.
  2. Rambau P, Vierkant R, Intermaggio M, Kelemen L, Goodman M, Herpel E et al. Association of p16 expression with prognosis varies across ovarian carcinoma histotypes: an Ovarian Tumor Tissue Analysis consortium study. The Journal of Pathology: Clinical Research. 2018;4:250-61.
  3. Pujani M, Choudhury M, Goyal S. A cytohistological study of Ki67 expression in ovarian tumors. Indian Journal of Pathology and Microbiology. 2011;54:21.
  4. Sallum L, Andrade L, Bastos Eloy da Costa L, Ramalho S, Ferracini A, Natal R et al. BRCA1, Ki67, and β-Catenin Immunoexpression Is Not Related to Differentiation, Platinum Response, or Prognosis in Women With Low- and High-Grade Serous Ovarian Carcinoma. International Journal of Gynecologic Cancer. 2019;28:437-47.
  5. Pawel Surowiak, Verena Materna, Adam Maciejczyk, Marek Pudelko,Decreased expression of p16 in ovarian cancers represents an unfavourable prognostic factor in 2008;23:531-38.
Statistics
Article View: 52
PDF Download: 63


Journal Management System. Powered by ejournalplus.com